The Clorox Company (NYSE:CLX) Stock Holdings Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in The Clorox Company (NYSE:CLX) by 0.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 752,986 shares of the company’s stock after purchasing an additional 4,866 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Clorox were worth $110,877,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Clorox by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company’s stock worth $2,293,135,000 after purchasing an additional 65,924 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Clorox by 0.4% during the fourth quarter. Stifel Financial Corp now owns 2,344,408 shares of the company’s stock valued at $380,761,000 after acquiring an additional 9,582 shares during the period. Northern Trust Corp raised its holdings in shares of Clorox by 18.2% during the fourth quarter. Northern Trust Corp now owns 1,494,265 shares of the company’s stock valued at $242,684,000 after acquiring an additional 230,173 shares during the period. Balyasny Asset Management L.P. raised its holdings in shares of Clorox by 28.7% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,421,909 shares of the company’s stock valued at $230,932,000 after acquiring an additional 316,688 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Clorox by 12.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,115,772 shares of the company’s stock valued at $181,213,000 after acquiring an additional 123,200 shares during the period. 78.53% of the stock is currently owned by institutional investors.

Clorox Stock Performance

CLX stock opened at $122.15 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The company has a market capitalization of $15.05 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 1.00 and a beta of 0.49. The Clorox Company has a 12 month low of $117.35 and a 12 month high of $171.37. The firm has a 50 day moving average of $125.35 and a two-hundred day moving average of $137.38.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.82 earnings per share. As a group, equities analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Shareholders of record on Wednesday, August 13th will be given a $1.24 dividend. This is a positive change from Clorox’s previous quarterly dividend of $1.22. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Wednesday, August 13th. Clorox’s payout ratio is presently 74.85%.

Analyst Ratings Changes

A number of research firms have recently issued reports on CLX. Jefferies Financial Group cut their price target on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Barclays cut their price target on shares of Clorox from $129.00 to $119.00 and set an “underweight” rating on the stock in a report on Tuesday, July 15th. Morgan Stanley cut their price target on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. UBS Group cut their price target on shares of Clorox from $150.00 to $134.00 and set a “neutral” rating on the stock in a report on Thursday, July 17th. Finally, Evercore ISI set a $140.00 price target on shares of Clorox and gave the company an “underperform” rating in a report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $143.36.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.